- Home
- LPL vs ATAI Comparison
LPL vs ATAI Comparison
Compare LPL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPL | ATAI |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2004 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LPL | ATAI |
|---|---|---|
| Price | $3.32 | $7.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 2.2M | ★ 12.1M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $2.76 | $3.27 |
| 52 Week High | $5.83 | $7.45 |
Technical Indicators
Market Signals| Indicator | LPL | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 61.65 |
| Support Level | $2.76 | $3.32 |
| Resistance Level | $3.43 | N/A |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 5.26 | 45.45 |
Price Performance
Historical ComparisonAbout LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.